Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

Xenobiotica

Volumn 44, Issue 4, 2014, Pages 352-368

  Ho, May Y K ^a   Morris, Michael J ^a   Pirhalla, Jill L ^a   Bauman, John W ^a   Pendry, Carolyn B ^a   Orford, Keith W ^a   Morrison, Royce A ^b   Cox, Donna S ^a  

^a GLAXOSMITHKLINE   (United States)

^b GlaxoSmithKline ^*  (United States)

Author keywords

ADME; Human metabolites; Long elimination half life; Oncology; Trametinib

Indexed keywords

ACYLTRANSFERASE; CARBON 14; DRUG METABOLITE; GLUCURONIDE; TRAMETINIB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CLINICAL ARTICLE; DEACETYLATION; DOSIMETRY; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TOLERABILITY; FECES ANALYSIS; HUMAN; LIVER CELL CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MIDDLE AGED; OPEN STUDY; RADIOACTIVITY; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, ORAL; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; RADIOMETRY; RADIOPHARMACEUTICALS; RATS; SKIN NEOPLASMS;

EID: 84896767254     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.831143     Document Type: Article

References (28)

1. Ametzazurra A, Larrea E, Civeira MP, et al. (2008). Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis. Oncogene 27:7296-306.
2. Anderson NG, Maller JL, Tonks NK, Sturgill TW. (1990). Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343:651-3.
3. Blesa JMG, Pulido EG, Pulla MP, Candel VA. (2009). Treatment options for metastatic melanoma. A systematic review. Canc Ther 7:188-99.
4. Breyer-Pfaff U, Wachsmuth H. (2001). Tertiary N-glucuronides of clozapine and its metabolite desmethylclozapine in patient urine. Drug Metab Dispos 29:1343-8. (Pubitemid 32896585)
5. Chapman PB, Hauschild A, Robert C, et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 364:2507-16.
6. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. (2004). Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16. (Pubitemid 38134055)
7. Falchook GS, Lewis KD, Infante JR, et al. (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase I dose-escalation trial. Lancet Oncol 13:782-9.
8. Fremin C, Meloche S. (2010). From basic research to clinical development fo MEK 1/2 inhibitors for cancer therapy. J Hematol Oncol 3:8.
9. Flaherty KT, Robert C, Hersey P, et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-14.
10. Gilmartin AG, Bleam MR, Groy A, et al. (2011). GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17:989-1000.
11. Gschwind HP, Pfaar U, Waldmeier F, et al. (2005). Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503-12. (Pubitemid 41323999)
12. Hodi FS, O'Day SJ, McDermott DF, et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23.
13. Hop C, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling method to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901-3. (Pubitemid 28319423)
14. ICRP (1992). Radiological protection in biomedical research. ICRP Publication 62. Ann. ICRP 22:3-4.
15. Infante JR, LaFecher LA, Falchook GS, et al. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13:773-81.
16. Kamb A, Wee S, Lengauer C. (2007). Why is cancer drug discovery so difficult? Nat Rev Drug Discov 6:115-20. (Pubitemid 46745339)
17. Lemech C, Infante J, Arkenau H. (2012). The potential for BRAFV600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol 4:61-73.
18. Madan A, Fisher A, Jim L, et al. (2007). In vitro metabolism of Indiplon and an assessment of its drug interaction potential. Xenobioticia 37: 736-52. (Pubitemid 47057123)
19. McArthur GA. (2012). The coming of age of MEK. Lancet Oncol 13: 744-5.
20. Nicholls AW, Lindon JC, Farrant RD, et al. (1999). Directly-coupled HPLC-NMR spectroscopic studies of metabolism and futile deacetylation of phenacetin in the rat. J Pharm Biomed Anal 20:865-73. (Pubitemid 29401955)
21. Ray LB, Sturgill TW. (1988). Characterization of insulin-stimulated microtubule-associated protein kinase. Rapid isolation and stabilization of a novel serine/threonine kinase from 3T3-L1 cells. J Biol Chem 263:12721-7. (Pubitemid 19000458)
22. Roffey S, Obach RS, Gedge JI, Smith D. (2007). What is the objective of the Mass Balance Study? A retrospective analysis of data in animal and human excretion studies employing radiolabelled drugs. Drug Metab Rev 39:17-43.
23. Tomoda A, Yamaguchi J, Kojima H, et al. (1986). Mechanism of oaminophenol metabolism in human erythrocytes. FEBS Lett 196: 44-8. (Pubitemid 16048182)
24. Toutain PL, Bousquet-Melou A. (2004). Volumes of distribution. J Vet Pharmacol Therap 27:441-53. (Pubitemid 39665131)
25. van Hogezand RA, Kennis HM, van Schaik A, et al. (1992). Bacterial acetylation of 5-aminosalicylic acid in fecal suspension cultured under aerobic and anaerobic conditions. Eur J Clin Pharmacol 43:189-92.
26. Yuan J, Yang D, Zhang J, et al. (2002). Disposition of a specific cyclooxygenase-2, Valdecoxib, in human. Drug Metab Dispos 30: 1013-21.
27. Zandvliet AS, Copalu W, Schellens JHM, et al. (2006). Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug Metab Dispos 34:1041-6. (Pubitemid 43763763)
28. Zhao JS, Singh A, Huang XD, Ward OP. (2000). Biotransformation of hydroxyaminobenzene and aminophenol by Pseudomonas putida 2NP8 cells grown in the presence of 3-nitrophenol. Appl Environ Microbiol 66:2336-42. (Pubitemid 30353935)